CLINICAL_TRIALS
trial_result
· 2020-07-08
Clinical Trial Update: A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine [Phase 3]
Summary
Phase 3 trial update for galcanezumab in adults with treatment-resistant migraine has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Migraine | Phase 3 | Status: COMPLETED | Results posted: 2020-07-08